Skip to content

cNEP for the Treatment of Obstructive Sleep Apnea

Continuous Negative External Pressure (cNEP) for the Treatment of Obstructive Sleep Apnea (OSA)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02677168
Acronym
cNEP
Enrollment
71
Registered
2016-02-09
Start date
2016-05-31
Completion date
2017-11-03
Last updated
2018-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Apnea, Obstructive

Keywords

obstructive sleep apnea, sleep apnea, OSA, cNEP, continuous negative external pressure

Brief summary

The purpose of this study is to determine whether cNEP (continuous positive external pressure) is effective in treating obstructive sleep apnea

Interventions

DEVICEcNEP

continuous negative external pressure

Sponsors

Sommetrics, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Key Inclusion Criteria: * PSG performed within the previous twelve months that documents the presence of obstructive sleep apnea (the qualifying PSG) * on that PSG, AHI must be 10 - 50/hr and \>80% of the apneas and hypopneas must be obstructive * no significant changes in health, medications, or lifestyle since the qualifying PSG Key

Exclusion criteria

* previous major surgery, injury or radiation to the neck * beard or excessive hair on the area of the neck where the collar will be applied * carotid artery disease * serious medical conditions * pregnancy * use of home oxygen * silicone allergy * sleep disturbance other than obstructive sleep apnea

Design outcomes

Primary

MeasureTime frameDescription
Sustained Response of reduction of AHI (apnea hypopnea index) at PSG (polysomnography) IIthree weeks--PSG II will be done after three weeks of home use of cNEP following PSG IA response (either initial or sustained) is defined as an AHI that is \< 50% of the qualifying PSG (polysomnography) that is also \< 15/hr
occurrence of adverse eventsthree weeksAdverse events that occur during the three weeks of cNEP home use.

Secondary

MeasureTime frameDescription
time of SpO2 (oxygen saturation) < 90%during each of the overnight PSGsthe number of minutes during the overnight PSG when SpO2 is \< 90% with cNEP in place
Initial Response of AHI at PSG Iup to 12 months after the qualifying PSGAn AHI (apnea hypopnea index) that is \<50% of that of the qualifying PSG, and \<15/hr at PSG I, with cNEP in place.
Three CGI (clinical global impression) subjective measuresthree weeks after the initiation of home cNEPSeven-item Likert CGI scales of three subjective measures: 1) subject's view of cNEP vs CPAP, 2) overall satisfaction with cNEP, 3) bed partner's feelings about cNEP.
hours of home use of cNEP per nightthree weeks after initiation of home cNEPthe number of hours of each night at home that the subject uses cNEP
Comparison of AHI at PSG I and PSG IIthree weeksThe AHI determined at PSG II will be compared with that of PSG I

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026